

## Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

**Description:** Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

### Scope

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Our summarization of the company's business strategy.
- SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

### Highlights

Boehringer Ingelheim GmbH (Boehringer) carries out research, development, manufacture and sale of pharmaceuticals. The company's products are used in the treatment of central nervous system, respiratory, cardiovascular, metabolic, urological and virological disorders. It has research and development facilities at six sites and operates 20 production plants in 13 countries. The company carries out its operations under three reportable segments, namely, Human Pharmaceuticals, Biopharmaceuticals and Animal Health. The company operates through 140 affiliated companies across the world. Boehringer is headquartered in Ingelheim, Germany.

### Boehringer Ingelheim GmbH Key Recent Developments

Aug 16, 2013: Boehringer Ingelheim Chemicals To Shut Down Petersburg Facility By 2014

Jul 17, 2013: Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

Jul 16, 2013: Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study

Jul 08, 2013: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

Jun 06, 2013: Boehringer Ingelheim Signs Strategic Alliance Agreement With Zhangjiang Biotech

### Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors' business structure and strategies with Our detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents:	List of Tables
	List of Figures
	Section 1 - About the Company
	Boehringer Ingelheim GmbH - Key Facts
	Boehringer Ingelheim GmbH - Key Employees
	Boehringer Ingelheim GmbH - Key Employee Biographies
	Boehringer Ingelheim GmbH - Major Products and Services
	Boehringer Ingelheim GmbH - Pharmaceutical Pipeline Products Data
	Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area
	Boehringer Ingelheim GmbH, Pipeline Products by Development Phase
	Boehringer Ingelheim GmbH - History
	Boehringer Ingelheim GmbH - Company Statement
	Boehringer Ingelheim GmbH - Locations And Subsidiaries
	Head Office
	Other Locations & Subsidiaries
	Affiliate
	Section 2 – Company Analysis
	Boehringer Ingelheim GmbH - Business Description
	Business Description - Animal Health
	Animal Health - Overview
	Animal Health - Financials
	Animal Health - Market View
	Animal Health - Technology
	Business Description - Biopharmaceuticals
	Biopharmaceuticals - Overview
	Biopharmaceuticals - Financials
	Business Description - Human Pharmaceuticals
	Human Pharmaceuticals - Overview
	Human Pharmaceuticals - Financials
	Human Pharmaceuticals - Market View
	Human Pharmaceuticals - Technology
	Boehringer Ingelheim GmbH - Corporate Strategy
	Boehringer Ingelheim GmbH - SWOT Analysis
	SWOT Analysis - Overview
	Boehringer Ingelheim GmbH - Strengths
	Strength - Broad Product Portfolio
	Strength - Growth Prospects: Pharmaceutical Outsourcing
	Strength - Geographical Diversity
	Strength - Delivering Value through Innovation
	Boehringer Ingelheim GmbH - Weaknesses
	Weakness - FDA Warning Letter
	Weakness - Pradaxa Lawsuit
	Weakness - Product Recalls
	Boehringer Ingelheim GmbH - Opportunities
	Opportunity - Strategic Alliances
	Opportunity - Market Growth in Emerging Economies
	Opportunity - Growing CRO Industry
	Boehringer Ingelheim GmbH - Threats
	Threat - Cost Containment Pressures
	Threat - Uncertain R&D Outcomes
	Threat - Stringent Government Regulations
	Threat - Increased Scrutiny on Imports
	Boehringer Ingelheim GmbH - Key Competitors
	Section 3 – Company’s Lifesciences Financial Deals and Alliances
	Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
	Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
	Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2007 to YTD 2013
	Boehringer Ingelheim GmbH, Medical Equipment, Deals By Type, 2007 to YTD 2013
	Boehringer Ingelheim GmbH, Recent Deals Summary
	Section 4 – Company’s Recent Developments
	Boehringer Ingelheim GmbH, Recent Developments
	Aug 16, 2013: Boehringer Ingelheim Chemicals To Shut Down Petersburg Facility By 2014
	Jul 17, 2013: Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

Jul 16, 2013: Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study  
Jul 08, 2013: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim  
Jun 06, 2013: Boehringer Ingelheim Signs Strategic Alliance Agreement With Zhangjiang Biotech  
May 22, 2013: Boehringer Ingelheim Responds To FDA Warning Letter  
May 17, 2013: Change in the Board of Managing Directors at Boehringer Ingelheim  
May 06, 2013: Boehringer Ingelheim joins Structural Genomics Consortium  
Apr 25, 2013: Boehringer Ingelheim Announces Strong 2012 Performance In China  
Apr 17, 2013: Argenta Announces Integrated Drug Discovery Collaboration With Boehringer Ingelheim  
Section 5 – Appendix  
Methodology  
About Us  
Contact Us  
Disclaimer

## List of Tables

Boehringer Ingelheim GmbH, Key Facts  
Boehringer Ingelheim GmbH, Key Employees  
Boehringer Ingelheim GmbH, Key Employee Biographies  
Boehringer Ingelheim GmbH, Major Products and Services  
Boehringer Ingelheim GmbH, Number of Pipeline Products by Therapy Area  
Boehringer Ingelheim GmbH, Number of Pipeline Products by Development Stage  
Boehringer Ingelheim GmbH, Pipeline Products By Therapy Area and Development Phase  
Boehringer Ingelheim GmbH, History  
Boehringer Ingelheim GmbH, Other Locations  
Boehringer Ingelheim GmbH, Subsidiaries  
Boehringer Ingelheim GmbH, Affiliate  
Boehringer Ingelheim GmbH, Key Competitors  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Type, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Recent Deals Summary

## List of Figures

Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area  
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2007 to YTD 2013  
Boehringer Ingelheim GmbH, Medical Equipment, Deals by Type, 2007 to YTD 2013

Ordering: Order Online - <http://www.researchandmarkets.com/reports/1368025/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.

## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

## Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review  
Web Address: <http://www.researchandmarkets.com/reports/1368025/>  
Office Code: OC8DIPNSOSNWPX

## Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 95
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 189
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 284

## Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr  Mrs  Dr  Miss  Ms  Prof

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Email Address: \* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organisation: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

Postal / Zip Code: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

**Payment Information**

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
  - American Express
  - Diners Club
  - Master Card
  - Visa

Cardholder's Name \_\_\_\_\_

Cardholder's Signature \_\_\_\_\_

Expiry Date \_\_\_\_\_ | \_\_\_\_\_

Card Number \_\_\_\_\_

CVV Number \_\_\_\_\_

Issue Date \_\_\_\_\_ | \_\_\_\_\_

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,  
Guinness Center,  
Taylors Lane,  
Dublin 8,  
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

**Please fax this form to:**  
**(646) 607-1907 or (646) 964-6609 - From USA**  
**+353-1-481-1716 or +353-1-653-1571 - From Rest of World**